Emerging ADC Combination Strategies in mTNBC

The panel explores the rationale and emerging data for combining ADCs with immunotherapy and other targeted agents. Panelists explain the biological rationale, including how ADCs may induce immunogenic cell death that enhances antigen presentation and recruits an adaptive immune response, providing a basis for pairing them with checkpoint inhibition. The discussion reviews randomized data evaluating a TROP2-directed ADC plus pembrolizumab against the prior chemotherapy-plus-pembrolizumab standard in the PD-L1–positive population, highlighting both efficacy signals and a safety profile consistent with the individual agents. Panelists also discuss earlier-phase combination data and ongoing randomized trials evaluating ADC-plus-checkpoint-inhibitor strategies in the first-line setting, noting these approaches are not yet available in clinic but are eagerly awaited. The conversation closes by acknowledging the broader unmet need that is driving combination development for later lines. Viewers gain a forward-looking view of where first-line and post-ADC strategies may be heading.